{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:46:49Z","timestamp":1789660009950,"version":"4.0.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100010289","name":"Funda\u00e7\u00e3o Gr\u00fcnenthal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40122-026-00834-x","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T07:37:17Z","timestamp":1776411437000},"page":"765-784","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A European Delphi Consensus to Support the Diagnosis, Management, and Appropriate Positioning of Topical Treatments for Postherpetic Neuralgia (PHN)"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2630-7647","authenticated-orcid":false,"given":"Andrea","family":"Truini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Bhaskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9668-3103","authenticated-orcid":false,"given":"Diego","family":"Fornasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Bouhassira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9492-4698","authenticated-orcid":false,"given":"Ralf","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisele","family":"Pickering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"834_CR1","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4065\/84.3.274","volume":"84","author":"P Sampathkumar","year":"2009","unstructured":"Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009;84:274\u201380.","journal-title":"Mayo Clin Proc"},{"key":"834_CR2","first-page":"861","volume":"5","author":"M Tontodonati","year":"2012","unstructured":"Tontodonati M, Ursini T, Polilli E, et\u00a0al. Post-herpetic neuralgia. Int J Gen Med. 2012;5:861.","journal-title":"Int J Gen Med"},{"key":"834_CR3","unstructured":"International Longevity Centre. Painfully unaware: improving older people\u2019s understanding of shingles vaccination in an ageing society 2023. https:\/\/ilcuk.org.uk\/wp-content\/uploads\/2024\/04\/ILC-Painfully-Unaware.pdf. Accessed 2 Oct 2025."},{"key":"834_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3344\/kjp.2020.33.3.201","volume":"33","author":"G Singh","year":"2020","unstructured":"Singh G, Song S, Choi E, et\u00a0al. Recombinant zoster vaccine (Shingrix\u00ae): a new option for the prevention of herpes zoster and postherpetic neuralgia. Korean J Pain. 2020;33:201.","journal-title":"Korean J Pain"},{"key":"834_CR5","doi-asserted-by":"publisher","DOI":"10.4103\/ijdvl.IJDVL_1021_16","volume":"84","author":"E Koshy","year":"2018","unstructured":"Koshy E, Mengting L, Kumar H, et\u00a0al. Epidemiology, treatment and prevention of herpes zoster: a comprehensive review. Indian J Dermatol Venereol Leprol. 2018;84:251.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"834_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2147\/JMDH.S106340","volume":"9","author":"T Mallick-Searle","year":"2016","unstructured":"Mallick-Searle T, Snodgrass B, Brant JM. Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology. J Multidiscip Healthc. 2016;9:447.","journal-title":"J Multidiscip Healthc"},{"key":"834_CR7","volume-title":"Postherpetic neuralgia. StatPearls [Internet]","author":"C Gruver","year":"2023","unstructured":"Gruver C, Guthmiller KB. Postherpetic neuralgia. StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2023."},{"key":"834_CR8","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40266-012-0014-3","volume":"29","author":"S Nalamachu","year":"2012","unstructured":"Nalamachu S, Morley-Forster P. Diagnosing and managing postherpetic neuralgia. Drugs Aging. 2012;29:863.","journal-title":"Drugs Aging"},{"key":"834_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3395-z","volume":"18","author":"D Curran","year":"2018","unstructured":"Curran D, Schmidt-Ott R, Schutter U, et\u00a0al. Impact of herpes zoster and postherpetic neuralgia on the quality of life of Germans aged 50 or above. BMC Infect Dis. 2018;18:496.","journal-title":"BMC Infect Dis"},{"key":"834_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/749698","volume":"2014","author":"T Weinke","year":"2014","unstructured":"Weinke T, Glogger A, Bertrand I, et\u00a0al. The societal impact of herpes zoster and postherpetic neuralgia on patients, life partners, and children of patients in Germany. Sci World J. 2014;2014:749698.","journal-title":"Sci World J"},{"key":"834_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-529","volume":"14","author":"M Duracinsky","year":"2014","unstructured":"Duracinsky M, Paccalin M, Gavazzi G, et\u00a0al. ARIZONA study: is the risk of post-herpetic neuralgia and its burden increased in the most elderly patients? BMC Infect Dis. 2014;14:529.","journal-title":"BMC Infect Dis"},{"key":"834_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S1474-4422(25)00068-7","volume":"24","author":"N Soliman","year":"2025","unstructured":"Soliman N, Moisset X, Ferraro MC, et\u00a0al. Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis. Lancet Neurol. 2025;24:413\u201328.","journal-title":"Lancet Neurol"},{"key":"834_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.neurol.2020.01.361","volume":"176","author":"X Moisset","year":"2020","unstructured":"Moisset X, Bouhassira D, Avez Couturier J, et\u00a0al. Pharmacological and non-pharmacological treatments for neuropathic pain: systematic review and French recommendations. Rev Neurol (Paris). 2020;176:325\u201352.","journal-title":"Rev Neurol (Paris)"},{"key":"834_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s42466-020-00063-3","volume":"2","author":"T Schlereth","year":"2020","unstructured":"Schlereth T. Guideline, \u201cdiagnosis and non interventional therapy of neuropathic pain\u201d of the German Society of Neurology (deutsche Gesellschaft f\u00fcr Neurologie). Neurol Res Pract. 2020;2:16.","journal-title":"Neurol Res Pract"},{"key":"834_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2147\/TCRM.S58844","volume":"10","author":"R Casale","year":"2014","unstructured":"Casale R, Mattia C. Building a diagnostic algorithm on localized neuropathic pain (LNP) and targeted topical treatment: focus on 5% lidocaine-medicated plaster. Ther Clin Risk Manag. 2014;10:259\u201368.","journal-title":"Ther Clin Risk Manag"},{"key":"834_CR16","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1097\/j.pain.0000000000003239","volume":"165","author":"S Muller","year":"2024","unstructured":"Muller S, Bailey J, Bajpai R, et\u00a0al. Risk of adverse outcomes during gabapentinoid therapy and factors associated with increased risk in UK primary care using the Clinical Practice Research Datalink: a cohort study. Pain. 2024;165:2282\u201390.","journal-title":"Pain"},{"key":"834_CR17","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.2147\/DDDT.S328228","volume":"15","author":"M Voute","year":"2021","unstructured":"Voute M, Morel V, Pickering G. Topical lidocaine for chronic pain treatment. Drug Des Devel Ther. 2021;15:4091\u2013103.","journal-title":"Drug Des Devel Ther"},{"key":"834_CR18","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.2147\/JPR.S435809","volume":"17","author":"G Pickering","year":"2024","unstructured":"Pickering G, Engelen S, Stupar M, et\u00a0al. Is the capsaicin 179 mg (8% w\/w) cutaneous patch an appropriate treatment option for older patients with peripheral neuropathic pain? J Pain Res. 2024;17:1327\u201344.","journal-title":"J Pain Res"},{"key":"834_CR19","first-page":"541","volume":"23","author":"X Liu","year":"2020","unstructured":"Liu X, Wei L, Zeng Q, et\u00a0al. The treatment of topical drugs for postherpetic neuralgia: a network meta-analysis. Pain Physician. 2020;23:541\u201351.","journal-title":"Pain Physician"},{"key":"834_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/papr.13423","volume":"25","author":"EJM Adriaansen","year":"2024","unstructured":"Adriaansen EJM, Jacobs JG, Vernooij LM, et\u00a0al. 8. Herpes zoster and post herpetic neuralgia. Pain Pract. 2024;25:e13423.","journal-title":"Pain Pract"},{"key":"834_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2217\/pmt-2021-0022","volume":"12","author":"MA \u00dcberall","year":"2022","unstructured":"\u00dcberall MA, Eerdekens M, Hollanders E, et\u00a0al. Lidocaine 700 mg medicated plaster for postherpetic neuralgia: real-world data from the German pain E-registry. Pain Manag. 2022;12:195\u2013209.","journal-title":"Pain Manag"},{"key":"834_CR22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1600-0404.2010.01433.x","volume":"123","author":"RF Wolff","year":"2011","unstructured":"Wolff RF, Bala MM, Westwood M, et\u00a0al. 5% lidocaine-medicated plaster vs other relevant interventions and placebo for post-herpetic neuralgia (PHN): a systematic review. Acta Neurol Scand. 2011;123:295\u2013309.","journal-title":"Acta Neurol Scand"},{"key":"834_CR23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/20494637231201502","volume":"18","author":"MP Santos","year":"2023","unstructured":"Santos MP, Lemos F, Gomes J, et\u00a0al. Topical capsaicin 8% patch in peripheral neuropathic pain: efficacy and quality of life. Br J Pain. 2023;18:42.","journal-title":"Br J Pain"},{"key":"834_CR24","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40122-025-00733-7","volume":"14","author":"S Nalamachu","year":"2025","unstructured":"Nalamachu S, Mallick-Searle T, Adler J, et\u00a0al. Multimodal therapies for the treatment of neuropathic pain: the role of lidocaine patches in combination therapy: a narrative review. Pain Ther. 2025;14:865\u201379.","journal-title":"Pain Ther"},{"key":"834_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/AJP.0b013e318227403d","volume":"28","author":"GA Irving","year":"2012","unstructured":"Irving GA, Backonja M, Rauck R, et\u00a0al. NGX-4010, a capsaicin 8% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia. Clin J Pain. 2012;28:101\u20137.","journal-title":"Clin J Pain"},{"key":"834_CR26","unstructured":"National Institute for Health and Care Excellence. Recommendations | neuropathic pain in adults: pharmacological management in non-specialist settings | clinical guideline | CG173. Last updated: 22 Sept 2020. 2013."},{"key":"834_CR27","unstructured":"National Institute for Health and Care Excellence. CKS. Scenario: prevention | management | Shingles 2025. https:\/\/cks.nice.org.uk\/topics\/post-herpetic-neuralgia\/management\/management\/. Accessed 2 Oct 2025."},{"key":"834_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004326","author":"WT Gattrell","year":"2024","unstructured":"Gattrell WT, Logullo P, van Zuuren EJ, et\u00a0al. ACCORD (Accurate Consensus Reporting Document): a reporting guideline for consensus methods in biomedicine developed via a modified Delphi. PLoS Med. 2024. https:\/\/doi.org\/10.1371\/journal.pmed.1004326.","journal-title":"PLoS Med"},{"key":"834_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032829","volume":"102","author":"Z Shang","year":"2023","unstructured":"Shang Z. Use of Delphi in health sciences research: a narrative review. Medicine. 2023;102:E32829.","journal-title":"Medicine"},{"key":"834_CR30","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","volume":"67","author":"IR Diamond","year":"2014","unstructured":"Diamond IR, Grant RC, Feldman BM, et\u00a0al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol. 2014;67:401\u20139.","journal-title":"J Clin Epidemiol"},{"key":"834_CR31","unstructured":"World Health Organization. WHO position paper on herpes zoster vaccines 2024. https:\/\/www.who.int\/publications\/i\/item\/WER10027-28-265-284. Accessed 30 Oct 2025."},{"key":"834_CR32","unstructured":"European Medicines Agency. Shingrix, INN-Herpes zoster vaccine (recombinant, adjuvanted). 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/shingrix-epar-product-information_en.pdf. Accessed 2 Oct 2025."},{"key":"834_CR33","unstructured":"Vaccine Scheduler | ECDC 2025. https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByCountry?SelectedCountryId=6&IncludeChildAgeGroup=true&IncludeChildAgeGroup=false&IncludeAdultAgeGroup=true&IncludeAdultAgeGroup=false. Accessed 2 Oct 2025."},{"key":"834_CR34","unstructured":"Sant\u00e9 publique France. 2025 simplified vaccination schedule 2025. https:\/\/share.google\/Y6Q3ZyTRlJ8UVXca1. Accessed 2 Oct 2025."},{"key":"834_CR35","unstructured":"Ministero della Salute. Calendario nazionale vaccinale. 2023. https:\/\/www.trovanorme.salute.gov.it\/norme\/dettaglioAtto?id=95963&articolo=3#articoli. Accessed 2 Oct 2025."},{"key":"834_CR36","unstructured":"Shingles: symptoms, causes, diagnosis and treatments 2024. https:\/\/www2.hse.ie\/conditions\/shingles\/. Accessed 2 Oct 2025."},{"key":"834_CR37","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1080\/15360288.2023.2174632","volume":"37","author":"E G\u00f3nima Valero","year":"2023","unstructured":"G\u00f3nima Valero E, Mendoza WAS, Sarmiento DA, et\u00a0al. Analgesic treatment approach for postherpetic neuralgia: a narrative review. J Pain Palliat Care Pharmacother. 2023;37:184\u201393.","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"834_CR38","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1185\/03007995.2010.483675","volume":"26","author":"S Rehm","year":"2010","unstructured":"Rehm S, Binder A, Baron R. Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study. Curr Med Res Opin. 2010;26:1607\u201319.","journal-title":"Curr Med Res Opin"},{"key":"834_CR39","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1185\/03007990903048078","volume":"25","author":"R Baron","year":"2009","unstructured":"Baron R, Mayoral V, Leijon G, et\u00a0al. Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. Curr Med Res Opin. 2009;25:1677\u201387.","journal-title":"Curr Med Res Opin"},{"key":"834_CR40","first-page":"99","volume":"12","author":"GA Irving","year":"2011","unstructured":"Irving GA, Backonja MM, Dunteman E, et\u00a0al. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Clin J Pain. 2011;12:99\u2013109.","journal-title":"Clin J Pain"},{"key":"834_CR41","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1080\/14656566.2020.1759550","volume":"21","author":"C Bonezzi","year":"2020","unstructured":"Bonezzi C, Costantini A, Cruccu G, et\u00a0al. Capsaicin 8% dermal patch in clinical practice: an expert opinion. Expert Opin Pharmacother. 2020;21:1377\u201387.","journal-title":"Expert Opin Pharmacother"},{"key":"834_CR42","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000702","volume":"3","author":"M Devor","year":"2018","unstructured":"Devor M. Rethinking the causes of pain in herpes zoster and postherpetic neuralgia: the ectopic pacemaker hypothesis. Pain Rep. 2018;3:e702. https:\/\/doi.org\/10.1097\/PR9.0000000000000702.","journal-title":"Pain Rep"},{"key":"834_CR43","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1046\/j.1365-2648.2003.02537.x","volume":"41","author":"C Powell","year":"2003","unstructured":"Powell C. The Delphi technique: myths and realities. J Adv Nurs. 2003;41:376\u201382. https:\/\/doi.org\/10.1046\/j.1365-2648.2003.02537.x.","journal-title":"J Adv Nurs"},{"key":"834_CR44","unstructured":"Summary of product characteristic (emc). Lidocaine Grunenthal 700 mg medicated plaster 2024. https:\/\/www.medicines.org.uk\/emc\/product\/2469\/pil. Accessed 3 Oct 2025."},{"key":"834_CR45","unstructured":"Specialist Pharmacy Service. Using transdermal patches safely in healthcare settings 2025. https:\/\/www.sps.nhs.uk\/articles\/using-transdermal-patches-safely-in-healthcare-settings\/. Accessed 3 Oct 2025."},{"key":"834_CR46","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/jpm15050191","volume":"15","author":"YT Wu","year":"2025","unstructured":"Wu YT, Lao HC, Kao SC, et\u00a0al. From consultation to collaboration: a patient-centered approach to shingles pain and postherpetic neuralgia management. J Pers Med. 2025;15:191.","journal-title":"J Pers Med"},{"key":"834_CR47","first-page":"162","volume":"18","author":"D B\u0119ben","year":"2024","unstructured":"B\u0119ben D, Kowalewski J, Recka K, et\u00a0al. Post-herpetic neuralgia: currently available oral and topical medications in the management of pain\u2014A review. J Preclin Clin Res. 2024;18:162\u20137.","journal-title":"J Preclin Clin Res"},{"key":"834_CR48","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1080\/14656566.2017.1392508","volume":"18","author":"J Schutzer-Weissmann","year":"2017","unstructured":"Schutzer-Weissmann J, Farquhar-Smith P. Post-herpetic neuralgia \u2013 A review of current management and future directions. Expert Opin Pharmacother. 2017;18:1739\u201350.","journal-title":"Expert Opin Pharmacother"},{"key":"834_CR49","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.pain.2003.12.024","volume":"108","author":"D Bouhassira","year":"2004","unstructured":"Bouhassira D, Attal N, Fermanian J, et\u00a0al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004;108:248\u201357.","journal-title":"Pain"},{"key":"834_CR50","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/ejp.1378","volume":"23","author":"S Perrot","year":"2019","unstructured":"Perrot S, Lant\u00e9ri-Minet M. Patients\u2019 global impression of change in the management of peripheral neuropathic pain: clinical relevance and correlations in daily practice. Eur J Pain. 2019;23:1117\u201328.","journal-title":"Eur J Pain"},{"key":"834_CR51","volume":"2017","author":"L Feller","year":"2017","unstructured":"Feller L, Khammissa RAG, Fourie J, et\u00a0al. Postherpetic neuralgia and trigeminal neuralgia. Pain Res Treat. 2017;2017:1681765.","journal-title":"Pain Res Treat"},{"key":"834_CR52","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/17843286.2024.2350258","volume":"79","author":"AF Nikkels","year":"2024","unstructured":"Nikkels AF, Schoevaerdts D, Kauffmann F, et\u00a0al. Herpes zoster in Belgium: a new solution to an old problem. Acta Clin Belg. 2024;79:205\u201316.","journal-title":"Acta Clin Belg"},{"key":"834_CR53","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/2051013615599151","volume":"3","author":"RW Johnson","year":"2015","unstructured":"Johnson RW, Alvarez-Pasquin M-J, Bijl M, et\u00a0al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 2015;3:109\u201320.","journal-title":"Ther Adv Vaccines"},{"key":"834_CR54","first-page":"55","volume":"18","author":"GE Gross","year":"2020","unstructured":"Gross GE, Eisert L, Doerr HW, et\u00a0al. S2k guidelines for the diagnosis and treatment of herpes zoster and postherpetic neuralgia. JDDG. 2020;18:55\u201378.","journal-title":"JDDG"}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-026-00834-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-026-00834-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-026-00834-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:34:58Z","timestamp":1778682898000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-026-00834-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["834"],"URL":"https:\/\/doi.org\/10.1007\/s40122-026-00834-x","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrea Truini has received consultancy fees from Amgen, AbbVie, Exeltis, Gr\u00fcnenthal, Pharmaline, and Viatris. Diego Fornasari has received fees as consultant or congress speaker or member of advisory boards from Angelini, Alfasigma, Abiogen, Chiesi, Gr\u00fcnenthal, Molteni, Sandoz, SPA, Viatris, and Zambon. Ralf Baron has received grant\/research support from: Europain (115007), DOLORisk (633491), IMI Paincare (777500), German Federal Ministry of Education and Research (BMBF): Verbundprojekt: Fr\u00fchdetektion von Schmerzchronifizierung (NoChro) (13GW0338C), German Research Network on Neuropathic Pain (01EM0903), Pfizer Pharma GmbH, Gr\u00fcnenthal GmbH, Mundipharma Research GmbH and Co. KG., Alnylam Pharmaceuticals Inc., Zambon GmbH, Sanofi Aventis GmbH, and Viatris; speaker fees from: Pfizer Pharma GmbH, Sanofi Aventis GmbH, Gr\u00fcnenthal GmbH, Mundipharma, Lilly GmbH, Desitin Arzneimittel GmbH, Teva GmbH, Bayer AG, MSD GmbH, Seqirus Australia Pty. Ltd., Novartis Pharma GmbH, TAD Pharma GmbH, Gr\u00fcnenthal SA Portugal, Gr\u00fcnen-thal Pharma AG Schweiz, Gr\u00fcnenthal B.V. Niederlande, Evapharma, Takeda Pharmaceuticals International AG Schweiz, Ology Medical Education Netherlands, Ever Pharma GmbH, Amicus Therapeutics GmbH, Novo Nordisk Pharma GmbH, Chiesi GmbH, Stada Mena DWC LLC Dubai, Hexal AG, Viatris, AstraZeneca GmbH, Sandoz, Aristo, Esanum, and Docflix GmbH; consultancy fees from: Pfizer Pharma GmbH, Sanofi Aventis GmbH, Gr\u00fcnenthal GmbH, Lilly, Novartis Pharma GmbH, Bristol-Myers Squibb, Biogenidec, AstraZeneca GmbH, Daiichi Sankyo, Glenmark Pharmaceuticals S.A., Seqirus Australia Pty. Ltd., Teva Pharmaceuticals Europe Niederlande, Teva GmbH, Genentech, Mundipharma International Ltd. UK, Galapagos NV, Kyowa Kirin GmbH, Vertex Pharmaceuticals Inc., Biotest AG, Celgene GmbH, Desitin Arzneimittel GmbH, Regeneron Pharmaceuticals Inc. USA, Theranexus DSV CEA Frankreich, Abbott Products Operations AG Schweiz, Bayer AG, Gr\u00fcnenthal Pharma AG Schweiz, Akcea Therapeutics Germany GmbH, Asahi Kasei Pharma Corporation, AbbVie Deutschland GmbH and Co. KG, Air Liquide Sante International Frankreich, Alnylam Germany GmbH, Lateral Pharma Pty Ltd., Hexal AG, Angelini, Janssen, SIMR Biotech Pty Ltd. Australien, Confo Therapeutics N.V. Belgium, Merz Pharmaceuticals GmbH, Neumentum Inc., F. Hoffmann-La Roche Ltd. Switzerland, AlgoTherapeutix SAS France, Nanobiotix SA France, AmacaThera Inc. Canada, Hoba Therapeutics, Heat2Move, Resano GmbH, Esteve Pharmaceuticals SA, Aristo, Viatris, and Vertanical GmbH. Gisele Pickering has received honoraria from Gr\u00fcnenthal, GSK, and Opella Healthcare. Arun Bhaskar has nothing to disclose. Didier Bouhassira has nothing to disclose. Michael Collins has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The conduct of the study adhered to the ethical principles outlined in the Declaration of Helsinki\u00a0(2013). This study did not require ethics committee approval as it was a noninterventional opinion-based Delphi process involving HCPs and patients, with no collection of sensitive or participant-identifiable data. All responses were anonymous. A statement of consent was included at the start of the survey, and completion of the survey constituted informed consent. All respondents received a nominal fee for completing the survey. This study was not prospectively registered.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}